Key findings in metastatic breast cancer, presented at the ASCO 2020 Virtual Annual Meeting, ranged across all tumor subtypes.
Arguably, the top news in breast cancer was a plenary presentation addressing the role of locoregional therapy in advanced disease. Dr Harold Burstein, of Dana-Farber Cancer Institute, comments that this study indicates systemic therapy as the mainstay treatment for woman with newly diagnosed advanced disease and a tumor in the breast.
In triple-negative breast cancer, Dr Burstein highlights two studies. The KEYNOTE-355 study validates the addition of a checkpoint inhibitor in first-line therapy in women whose tumors are PD-L1 positive. The intriguing results of the SWOG S1416 trial, Dr Burstein comments, suggest that the use of PARP inhibition may extend beyond BRCA1 and BRCA2 breast cancers.
In HER2-positive breast cancer, an update of the HER2CLIMB study indicates that the combination of tucatinib, trastuzumab, and capecitabine continues to benefit women with HER2-positive disease. Dr Burstein expects that this combination will be a new standard of care, particularly in women with brain metastases.
In studies of ER-positive breast cancer, Dr Burstein reviews the BYLieve trial. Results of this study suggest that alpelisib has activity in women with a PIK3CA mutation who have already received a CDK4/6 inhibitor.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Studies in Metastatic Breast Cancer From ASCO 2020 - Medscape - Jun 23, 2020.
Comments